- Program
- CD22 CAR T
- Indications
- CD19 R/R, LBCL
- Phase
- 90% of Phase 1
- Program
- Multi-Specific CAR T
- Indications
- Heme Malignancies
- Phase
- 50% of Lead Selection
- Program
- Discovery Programs
- Indications
- Heme & Solid Tumors
- Phase
- 40% of Discovery
*Phase 3 may not be required if the preceding phase is registrational.